SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.9B
Q4 2022
Positions
71
Filings on Record
27
2019–present window
Filed
Feb 14, 2023
original filing

Summary

Boxer Capital, LLC reported $1.9B in U.S.-listed holdings across 71 positions for Q4 2022.

Its largest position, Prometheus Biosciences, represents 11.0% of the portfolio.

Compared with Q3 2022, the fund opened 6 new positions and exited 8.

Portfolio Metrics

Turnover
+18.2%
vs prior filed quarter
Top-10 Concentration
+50.0%
share of reported value
Largest Position
+11.0%
Prometheus Biosciences
New / Exited
6 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 75.1%Other: 17.0%ADR: 7.9%Equity WRT: 0.0%
  • Common Stock · 75.1% · $1.4B
  • Other · 17.0% · $322M
  • ADR · 7.9% · $150M
  • Equity WRT · 0.0% · $42,926

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AXSMAxsome Therapeutics IncNEW+400.0K400.0K+$31M$31M
GONGeron CorpNEW+8.10M8.10M+$20M$20M
OPHTEURIveric Bio IncNEW+825.0K825.0K+$18M$18M
VKTXViking Therapeutics IncNEW+1.50M1.50M+$14M$14M
ARVNArvinas IncNEW+150.0K150.0K+$5M$5M
IRONDisc Medicine IncNEW+130.0K130.0K+$175,500$175,500
FATEFate Therapeutics IncADDED+900.0K1.25M+$5M$13M
SRPTSAREPTA THERAPEUTICS INCSOLD OUT−200.0K0−$22M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Prometheus Biosciences IncCOM11.00%$209M1.90M
2ONCBeiGene Ltdhistory →SPONSORED ADR5.80%$110M500.0K
3CYTKCytokinetics Inchistory →COM NEW5.07%$96M2.10M
4RVMDRevolution Medicines Inchistory →COM5.00%$95M3.98M
5MRTXEURMirati Therapeutics Inchistory →COM4.78%$91M2.00M
6SWTXUSDSpringworks Therapeutics Inchistory →COM4.69%$89M3.42M
7APLSUSDApellis Pharmaceuticals Inchistory →COM4.30%$81M1.58M
8AMLXAmylyx Pharmaceuticals Inchistory →COM4.06%$77M2.08M
9TNGXTango Therapeutics Inchistory →COM2.72%$52M7.12M
10TYRATyra Biosciences Inchistory →COM2.58%$49M6.45M
11RETAEURReata Pharmaceuticals Inchistory →CL A2.46%$47M1.23M
12AKROAkero Therapeutics Inchistory →COM2.40%$46M831.5K
132662247DiTeos Therapeutics Inchistory →COM2.22%$42M2.15M
14SG7Sage Therapeutics Inchistory →COM2.20%$42M1.09M
15ANABAnaptysBio Inchistory →COM2.12%$40M1.30M
16IDYAIdeaya Biosciences Inchistory →COM2.11%$40M2.20M
17260Centessa Pharmaceuticals PLChistory →SPONSORED ADS2.04%$39M1.25M
18NUVLNuvalent Inchistory →COM1.90%$36M1.21M
19RLAYRelay Therapeutics Inchistory →COM1.71%$32M2.17M
20AXSMAxsome Therapeutics Inchistory →COM1.63%$31M400.0K
21RCUSArcus Biosciences Inchistory →COM1.56%$30M1.43M
22Merus N VCOM1.55%$29M1.90M
23RCKTRocket Pharmaceuticals Inchistory →COM1.51%$29M1.47M
24AM6Amicus Therapeutics Inchistory →COM1.50%$28M2.33M
25VTYXUSDVentyx Biosciences Inchistory →COM1.47%$28M850.0K
26PMVPPMV Pharmaceuticals Inchistory →COM1.45%$28M3.16M
27BLUBellus Health Inc Newhistory →COM NEW1.39%$26M3.20M
28DAWNGBXDay One Biopharmaceuticals Ihistory →COM1.35%$26M1.19M
29RNAGBPAvidity Biosciences Inchistory →COM1.31%$25M1.12M
30XENEXenon Pharmaceuticals Inchistory →COM1.25%$24M600.0K
31GONGeron Corphistory →COM1.03%$20M8.10M
32EX9Exelixis Inchistory →COM0.97%$18M1.15M
33Point Biopharma Global IncCOM0.96%$18M2.50M
34Prothena Corp PLCSHS0.95%$18M300.0K
35ETNBGBP89Bio Inchistory →COM0.94%$18M1.40M
36OPHTEURIveric Bio Inchistory →COM0.93%$18M825.0K
37Rain Oncology IncCOM0.91%$17M2.15M
38VKTXViking Therapeutics Inchistory →COM0.74%$14M1.50M
39NRIXNurix Therapeutics Inchistory →COM0.71%$13M1.22M
40FATEFate Therapeutics Inchistory →COM0.66%$13M1.25M
41Ascendis Pharma A/SSPONSORED ADR0.61%$12M95.0K
42CGEMCullinan Oncology Inchistory →COM0.60%$11M1.07M
43IOVAIovance Biotherapeutics IncCOM0.51%$10M1.51M
44ORICOric Pharmaceuticals IncCOM0.39%$7M1.05M
45GOSSGossamer Bio IncCOM0.38%$7M3.34M
46Panacea Acquisition Corp IICL A SHS0.33%$6M500.0K
47COGTCogent Biosciences IncCOM0.32%$6M525.0K
48BCABGBPBioAtla IncCOM0.30%$6M686.3K
49ARVNArvinas IncCOM0.27%$5M150.0K
50CABACabaletta Bio IncCOM0.26%$5M540.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.